Communiqués Disruptive Pharma AB

Actions

DPHA

SE0021181559

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
1,240 ^SEK	+7,83%		+2,48%	-15,65%

07/09	Strand Småbolagsfond progresse de 3,58 % en août - tendance solide sur les marchés actions	FW
27/07	Disruptive Pharma Holding Ab (Publ) a finalisé l'acquisition de Guard Therapeutics International AB (publ) (OM:GUARD) dans le cadre d'une fusion inversée.	CI

Communiqués

22/09	Disruptive Pharma divests GTX platform and retains rights to future royalty and milestone revenues	AQ
16/09	Disruptive Pharma : Tobias Assander joins Disruptive Pharma as Manufacturing and Process Development Lead	PU
18/08	Disruptive Pharma to ring the opening bell at Nasdaq Stockholm	AQ
27/07	Guard Therapeutics Completes Reverse Takeover of Disruptive Pharma and Executes In-Kind Share Issue	AQ
16/07	Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description	AQ
12/06	Guard Therapeutics Initiates Transaction Process for the GTX Platform	AQ
10/06	Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma	AQ
09/04	Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market	AQ
31/03	Guard Therapeutics provides update on strategic review	AQ
05/02	Guard Therapeutics Announces Changes to the Company’s Management Team	AQ
05/02	Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review	AQ
15/01	Guard Therapeutics Partners in EU Consortium For Alport Syndrome	AQ
30/12	Guard Therapeutics: Discontinuing coverage	AQ
16/12	Guard Therapeutics presents the Nomination Committee for 2026	AQ
08/12	Guard Therapeutics appoints Redeye as financial advisor in the strategic review	AQ
05/12	Guard Therapeutics changes Certified Adviser to Redeye AB	AQ
05/12	Guard Therapeutics: Challenging path forward	AQ
04/12	Guard Therapeutics Explores Strategic Alternatives	AQ
04/12	Guard Therapeutics Provides Assessment of Full POINTER Study Results	AQ
13/11	Guard Therapeutics: Awaiting further company communication – Q3 review	AQ
26/10/25	Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study	AQ
17/10/25	Guard Therapeutics to Present Late-Breaking Phase 2b POINTER Results at ASN Kidney Week 2025	AQ
05/10/25	Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study	AQ
30/09/25	Guard Therapeutics: POINTER data preview: high risk, high potential reward - corrected version	AQ
29/09/25	Guard Therapeutics: POINTER data preview: high risk, high potential reward	AQ